Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Accured Expenses: 2024-2025

Historic Change in Accured Expenses for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $12.7 million.

  • Kura Oncology's Change in Accured Expenses rose 124.03% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year change of. This contributed to the annual value of $15.2 million for FY2024, which is 47.19% up from last year.
  • Latest data reveals that Kura Oncology reported Change in Accured Expenses of $12.7 million as of Q3 2025, which was up 68.98% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Change in Accured Expenses peaked at $12.7 million during Q3 2025, and registered a low of -$5.4 million during Q1 2025.
  • Over the past 2 years, Kura Oncology's median Change in Accured Expenses value was $5.7 million (recorded in 2024), while the average stood at $4.3 million.
  • The largest annual percentage gain for Kura Oncology's Change in Accured Expenses in the last 5 years was 15,150.00% (2025), contrasted with its biggest fall of 73.50% (2025).
  • Kura Oncology's Change in Accured Expenses (Quarterly) stood at $12.7 million in 2024, then spiked by 124.03% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $7.5 million for Q2 2025, and -$5.4 million during Q1 2025.